> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alkermes Starts MS Drug Phase 3 Test
- URL: https://www.fdaweb.com/alkermes-starts-ms-drug-phase-3-test/
- Published: 2017-03-16T12:00:00.000Z
- Updated: 2026-09-14T22:12:00.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138220

Alkermes says it has started a new Phase 3 trial of its ALKS 8700, a novel, oral monomethyl fumarate prodrug candidate in development for treating relapsing forms of multiple sclerosis. The five-week head-to-head study is to evaluate the gastrointestinal tolerability of ALKS 8700 compared to Tecfidera (dimethyl fumarate) in about 420 patients with relapsing-remitting MS. The company says it plans to submit an NDA to FDA for ALKS 8700 in 2018 seeking an indication of treating relapsing-remitting MS.